Thank you, Theresa. So to summarize, like we heard, we had total revenues of 370 million, which is 1% growth compared to the same quarter in the previous year. And we have an operating profit of 143 million, which is a 3% decline compared to the same quarter in the last year. The margin was 39% and the earnings per share were at 1.21 cents per share. Operating cash flow was 52 million versus 98 million last year. If we look at the organic growth, we had an organic growth of 2% and a negative currency effect of 1%. So the currency effect in the quarter was quite small. Moving on to the gross margin, our overall margin was stable at 72%. Within Pediatrics, margin increased from 73% to 75%. And within adult health, it declined from 63% to 57%. The main reason for the variations in the margin, especially in adult health, is changes in the product mix. For example, as we mentioned previously, we had a quite large increase in sales in products like Gastrus. And, you know, those products have slightly lower gross margins than, for example, the protective tablets. So that explains why the mix change in the quarter explains why the margin is somewhat lower for the adult segment. Moving on to the operating expenses. Our operating expenses increased by 7%. If we look at the different lines, we see that our sales and marketing costs grew by 9%, mainly due to a higher activity level in different markets. As for the R&D costs, these costs grew by 34%. However, we have to remember they grew from a lower base. Due to that, we had quite low costs last year and the year before due to Covid restrictions on clinical studies. And we're more normalizing the costs now. That is why costs are increasing within R&D. Look at the administration. The costs grew from 4% to 2%. The cost here includes expenses for litigation. In Italy, and we have a total of extraordinary costs of about 5 million, which is mainly this line of admin costs. Then we have a line called other opex, which was a positive of 12 million versus 2 million last year. And this is due to an increase in exchange gains. So we have, so to speak, a negative cost here. So total opex then is 122 million. And then if you exclude adjustments of 5 million, we have an opex of 118 million versus 112 million. So it grew by 5%. If you would deduct the one-off items. Look at the P&L to summarize. Then sales grew by 1%, opex by 7%, and the EBIT decreased by 3%. We have a margin of 40%, 39%. And excluding the one-offs, a margin of 40% versus 41% last year. Looking at the cash flow. Cash flow from operating activities decreased by 47% to 52 million versus 98 million. And this is mainly due to higher costs in working capital resulting from increased receivables. We don't think there's anything special. It's more normal fluctuations within and between the quarters that cause this. So we will see in the coming quarter that the cash flow from those receivables will come in, and then the cash flow for the period is down 41 million and cash at the end of the period is 1.6 billion SEK. And as we announced before, we will pay out dividends, that will be decided by our annual general meeting today. There will be some dividend payments of 6.9, six per share, and a total of approximately 700 million out of that cash position, or 1.6 billion SEK. And with that, I hand over to Theresa for some concluding remarks.